PL3957320T3 - Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego - Google Patents

Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego

Info

Publication number
PL3957320T3
PL3957320T3 PL21174249.9T PL21174249T PL3957320T3 PL 3957320 T3 PL3957320 T3 PL 3957320T3 PL 21174249 T PL21174249 T PL 21174249T PL 3957320 T3 PL3957320 T3 PL 3957320T3
Authority
PL
Poland
Prior art keywords
glucosidase
treatment
acid alpha
pompe disease
augmented
Prior art date
Application number
PL21174249.9T
Other languages
English (en)
Inventor
Hung V. Do
Richie Khanna
Russell GOTSCHALL
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of PL3957320T3 publication Critical patent/PL3957320T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PL21174249.9T 2015-12-30 2016-12-29 Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego PL3957320T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08

Publications (1)

Publication Number Publication Date
PL3957320T3 true PL3957320T3 (pl) 2024-02-19

Family

ID=60186557

Family Applications (3)

Application Number Title Priority Date Filing Date
PL21174249.9T PL3957320T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego
PL23188938.7T PL4285902T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego
PL16826898T PL3397273T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL23188938.7T PL4285902T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego
PL16826898T PL3397273T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego

Country Status (16)

Country Link
EP (4) EP3397273B1 (pl)
CN (1) CN108472340A (pl)
CY (1) CY1124637T1 (pl)
DK (3) DK3957320T5 (pl)
ES (3) ES2965190T3 (pl)
FI (2) FI4285902T3 (pl)
HK (1) HK1253014A1 (pl)
HR (3) HRP20231465T1 (pl)
HU (2) HUE064049T2 (pl)
LT (3) LT3957320T (pl)
PL (3) PL3957320T3 (pl)
PT (3) PT4285902T (pl)
RS (3) RS64843B1 (pl)
SI (3) SI3957320T1 (pl)
SM (3) SMT202600054T1 (pl)
TW (3) TWI849380B (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP2857036B1 (en) 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2010254092B2 (en) * 2009-05-26 2015-11-12 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
SMT202100136T1 (it) 2012-05-03 2021-05-07 Amicus Therapeutics Inc Regimi posologici per il trattamento della malattia di pompe
WO2014014938A1 (en) 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
CN114540327B (zh) * 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶

Also Published As

Publication number Publication date
EP4706779A2 (en) 2026-03-11
PT3397273T (pt) 2021-08-09
ES2965190T3 (es) 2024-04-11
FI3957320T3 (fi) 2023-11-23
EP3397273A1 (en) 2018-11-07
DK3957320T3 (da) 2023-11-27
LT3957320T (lt) 2023-12-11
FI4285902T3 (fi) 2026-02-17
ES3063549T3 (en) 2026-04-17
TW202245831A (zh) 2022-12-01
PL3397273T3 (pl) 2021-12-06
ES2883844T3 (es) 2021-12-09
PL4285902T3 (pl) 2026-04-13
RS64843B1 (sr) 2023-12-29
SMT202600054T1 (it) 2026-03-09
RS67727B1 (sr) 2026-03-31
TW201726163A (zh) 2017-08-01
CY1124637T1 (el) 2022-07-22
DK3397273T3 (da) 2021-08-09
HUE064049T2 (hu) 2024-02-28
HRP20210894T1 (hr) 2021-07-23
SI3957320T1 (sl) 2024-01-31
SI3397273T1 (sl) 2021-11-30
SMT202300412T1 (it) 2024-01-10
EP4285902A3 (en) 2024-02-21
PT3957320T (pt) 2023-11-23
RS62212B1 (sr) 2021-09-30
SMT202100452T1 (it) 2021-09-14
DK3957320T5 (da) 2024-08-05
DK4285902T3 (da) 2026-02-16
TWI753874B (zh) 2022-02-01
HUE054733T2 (hu) 2021-09-28
SI4285902T1 (sl) 2026-04-30
EP4285902B1 (en) 2025-11-19
LT3397273T (lt) 2021-06-25
EP4285902A2 (en) 2023-12-06
HK1253014A1 (zh) 2019-06-06
EP3957320A1 (en) 2022-02-23
LT4285902T (lt) 2026-02-25
TW202506173A (zh) 2025-02-16
HRP20260120T1 (hr) 2026-03-13
EP3397273B1 (en) 2021-05-19
EP3957320B1 (en) 2023-08-23
HRP20231465T1 (hr) 2024-03-01
CN108472340A (zh) 2018-08-31
TWI849380B (zh) 2024-07-21
PT4285902T (pt) 2026-02-10

Similar Documents

Publication Publication Date Title
IL283837A (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
IL259133A (en) Jamkaban combinations for the treatment of cardiovascular disease
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
IL253945A0 (en) kdm1a inhibitors to treat the disease
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
ZA201907552B (en) Recombinant human acid alpha-glucosidase
IL255506A (en) A method for treating a neurological disease
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
EP3310377A4 (en) Method of treating crohn's disease
IL253726A0 (en) Preparations for the treatment of inflammatory diseases related to uric acid
GB201515244D0 (en) Treatment of inflammatory disease or condition
ES3063549T3 (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
GB201504413D0 (en) Treatment of disease
AU2015902286A0 (en) Method Of Treating Crohn's Disease
AU2015902358A0 (en) Treatment of inflammatory disease